| Autor: |
Klabukov I; Department of Regenerative Medicine, National Medical Research Radiological Center, 249031 Obninsk, Russia.; Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI, 115409 Obninsk, Russia.; Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia., Balyasin M; Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia., Krasilnikova O; Department of Regenerative Medicine, National Medical Research Radiological Center, 249031 Obninsk, Russia., Tenchurin T; National Research Centre 'Kurchatov Institute', 1, Akademika Kurchatova pl., 123182 Moscow, Russia., Titov A; City Clinical Hospital No. 67 of Moscow Health Department, 2/44, Salyama Adilya St., 123423 Moscow, Russia., Krasheninnikov M; Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia.; Lomonosov Institute of Fine Chemical Technologies, Russian Technological University MIREA, 119454 Moscow, Russia., Mudryak D; City Clinical Hospital No. 67 of Moscow Health Department, 2/44, Salyama Adilya St., 123423 Moscow, Russia.; Department of Hospital Surgery, Sklifosovsky Institute of Clinical Medicine, Sechenov University, 119435 Moscow, Russia., Sulina Y; Department of Obstetrics and Gynecology, Sechenov University, 119435 Moscow, Russia., Shepelev A; National Research Centre 'Kurchatov Institute', 1, Akademika Kurchatova pl., 123182 Moscow, Russia., Chvalun S; National Research Centre 'Kurchatov Institute', 1, Akademika Kurchatova pl., 123182 Moscow, Russia., Dyuzheva T; Department of Hospital Surgery, Sklifosovsky Institute of Clinical Medicine, Sechenov University, 119435 Moscow, Russia., Yakimova A; A. Tsyb Medical Research Radiological Center-Branch of the National Medical Research Radiological Center, Koroleva St. 4, 249036 Obninsk, Russia., Sosin D; Center for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, 125371 Moscow, Russia., Lyundup A; Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia., Baranovskii D; Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia.; A. Tsyb Medical Research Radiological Center-Branch of the National Medical Research Radiological Center, Koroleva St. 4, 249036 Obninsk, Russia., Shegay P; Department of Regenerative Medicine, National Medical Research Radiological Center, 249031 Obninsk, Russia.; Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia., Kaprin A; Department of Regenerative Medicine, National Medical Research Radiological Center, 249031 Obninsk, Russia.; Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia. |
| Abstrakt: |
Insufficient vascular growth in the area of artificial-material implantation contributes to ischemia, fibrosis, the development of bacterial infections, and tissue necrosis around the graft. The purpose of this study was to evaluate angiogenesis after implantation of polycaprolactone microfiber scaffolds modified by a pCMV-VEGF165-plasmid in rats. Influence of vascularization on scaffold degradation was also examined. We investigated flat microfibrous scaffolds obtained by electrospinning polycaprolactone with incorporation of the pCMV-VEGF-165 plasmid into the microfibers at concentrations of 0.005 ng of plasmid per 1 mg of polycaprolactone (0.005 ng/mg) (LCGroup) and 0.05 ng/mg (HCGroup). The samples were subcutaneously implanted in the interscapular area of rats. On days 7, 16, 33, 46, and 64, the scaffolds were removed, and a histological study with a morphometric evaluation of the density and diameter of the vessels and microfiber diameter was performed. The number of vessels was increased in all groups, as well as the resorption of the scaffold. On day 33, the vascular density in the HCGroup was 42% higher compared to the control group ( p = 0.0344). The dose-dependent effect of the pCMV-VEGF165-plasmid was confirmed by enhanced angiogenesis in the HCGroup compared to the LCGroup on day 33 ( p -value = 0.0259). We did not find a statistically significant correlation between scaffold degradation rate and vessel growth (the Pearson correlation coefficient was ρ = 0.20, p -value = 0.6134). Functionalization of polycaprolactone by incorporation of the pCMV-VEGF165 plasmid provided improved vascularization within 33 days after implantation, however, vessel growth did not seem to correlate with scaffold degradation rate. |
